Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
CHAMP: Study of NVK-002 in Children With Myopia
NCT03350620 · View on ClinicalTrials.gov ↗
Study Summary
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive myopia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NVK-002 Concentration 1
- DRUG NVK-002 Concentration 2
Study Locations (20)
California
- Site #015 — Berkeley
- Site #003 — Fullerton
- Site #016 — San Diego
Pennsylvania
- Site #011 — Elkins Park
- Site #017 — Lancaster
Washington
- Site #012 — Kirkland
- Site #020 — Spokane
Arizona
- Site #009 — Tucson
Connecticut
- Site #005 — Danbury
Florida
- Site #004 — Maitland
Illinois
- Site #024 — Peoria
Massachusetts
- Site #006 — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03350620
The ClinicalTrials.gov registry entry for NCT03350620 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyluma, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03350620 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, Pennsylvania, Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03350620 about?
NCT03350620 is a clinical study titled "CHAMP: Study of NVK-002 in Children With Myopia". Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or ...
What is the current status of trial NCT03350620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2017-11-20. Estimated completion is 2023-10-19.
What conditions does trial NCT03350620 study?
This clinical trial studies the following conditions: Myopia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03350620?
The interventions under investigation include: Placebo (DRUG), NVK-002 Concentration 1 (DRUG), NVK-002 Concentration 2 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03350620?
This trial is sponsored by Vyluma, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03350620 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.